Skip to content

Innate Immunity and the Allergic Response

Innate Immunity and the Allergic Response

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01494948
Enrollment
36
Registered
2011-12-19
Start date
2012-03-31
Completion date
2013-03-31
Last updated
2014-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasal Allergies

Brief summary

The purpose of this study is to determine if a certain cell type (the CD49d+ neutrophil) is associated with the presence or development of allergic disease.

Detailed description

A specific subset of neutrophils (CD49d+) will be recruited to the nasal tissue of individuals with allergic disease, and that these cells will also be found in the peripheral blood of allergic subjects. Normal subjects (those without atopy) and those treated for atopic disease will lack the presence of these cells.

Interventions

nasal challenges with antigen to which they are sensitive to

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
Medical College of Wisconsin
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Must give written informed consent before any study related activity is performed 2. Male and female adult and adolescent patients aged ≥18 years and ≤ 65 years. 3. Allergic or non-allergic subjects as proven by allergy skin tests in the past 2 years.

Exclusion criteria

1. The presence of any of these diseases: Atopic dermatitis, persistent controlled asthma, any level of severity of uncontrolled asthma, immunodeficiency or suspected immunodeficiency, any co-morbid disease (cardiac, congenital, diabetes, renal, gastrointestinal, hematologic, and oncologic). 2. Any prior history of immunodeficiency, cardiac, congenital, diabetes, renal, gastrointestinal, hematologic, or oncologic disease. 3. The use of any intranasal and inhaled corticosteroids within the last month. 4. Current therapy with any medication other than as needed over-the-counter medications or as-needed (not scheduled) antihistamine use. 5. Current pregnancy. 6. Women of childbearing potential not using an acceptable birth control method, as well as women who are breastfeeding 7. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required) 8. Use of any other investigational agent in the last 30 days

Design outcomes

Primary

MeasureTime frameDescription
Increase in percentage of CD49d expressing neutrophils in nasal lavage post allergen challenge.1monthNasal lavage on atopic and non-atopic adult subjects will be performed at baseline and following an allergen challenge. The frequency of CD49d expressing neutrophils in the lavage fluid will be determined by flow cytometry analysis, and the change in this frequency will be correlated with atopic status and allergen challenge. This is an observational study, procedures performed are not intended to impact the outcome of the individual participants.

Secondary

MeasureTime frameDescription
Change in immune cell numbers in the nasal lavage following allergen challenge1 monthThe numbers of neutrophils, CD49d+ neutrophils, lymphocytes, dendritic cells, and macrophages in the nasal lavage will be determined before and after allergen challenge. The outcome will be correlation of these changes with allergy status and any clinical symptoms of the allergen challenge (i.e., sneezing).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026